Patents Assigned to Intermune, Inc.
  • Anti-fibrotic pyridinones
    Patent number: 10898474
    Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: January 26, 2021
    Assignee: INTERMUNE, INC.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Johnnie Y. Ramphal, Kumaraswamy Emayan, Scott D. Seiwert
  • Anti-fibrotic pyridinones
    Patent number: 10544161
    Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: January 28, 2020
    Assignee: INTERMUNE, INC.
    Inventors: Johnnie Y. Ramphal, Brad Owen Buckman, Kumaraswamy Emayan, John Beamond Nicholas, Scott D. Seiwert
  • Anti-fibrotic pyridinones
    Patent number: 10376497
    Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 13, 2019
    Assignee: INTERMUNE, INC.
    Inventors: Brad O. Buckman, John Beamond Nicholas, Johnnie Y. Ramphal, Kumaraswamy Emayan, Scott D. Seiwert
  • Anti-fibrotic pyridinones
    Patent number: 10233195
    Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: March 19, 2019
    Assignee: INTERMUNE, INC.
    Inventors: Johnnie Y. Ramphal, Brad Owen Buckman, Kumaraswamy Emayan, John Beamond Nicholas, Scott D. Seiwert
  • Method of modulating stress-activated protein kinase system
    Patent number: 10010536
    Abstract: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 3, 2018
    Assignee: INTERMUNE, INC.
    Inventors: Lawrence M. Blatt, Scott D. Seiwert, Leonid D. Beigelman, Ramachandran Radhakrishnan, Karl Kossen, Vladimir Serebryany
  • Proteomic IPF markers
    Patent number: 9726677
    Abstract: Provided herein are novel biomarkers for the identification, prediction or monitoring of fibrotic pulmonary diseases (e.g. idiopathic pulmonary fibrosis (IPF)). The biomarkers provided herein may further be used for therapeutic treatment of IPF.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 8, 2017
    Assignee: INTERMUNE, INC.
    Inventors: Karl Kossen, Xiaoli Qin, Sharlene R. Lim, Scott S. Seiwert, Donald Ruhrmund
  • Methods of improving microvascular integrity
    Patent number: 9682071
    Abstract: The disclosure relates to methods of preserving or improving microvascular integrity in a patient in need thereof comprising administering pirfenidone therapy to the patient.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 20, 2017
    Assignees: INTERMUNE, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD
    Inventors: Mark R. Nicolls, Karl Kossen, Alan Cohen
  • Anti-fibrotic pyridinones
    Patent number: 9675593
    Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: June 13, 2017
    Assignee: INTERMUNE, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Johnnie Y. Ramphal, Kumaraswamy Emayan, Scott D. Seiwert
  • Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
    Patent number: 9561217
    Abstract: A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: February 7, 2017
    Assignee: INTERMUNE, INC.
    Inventors: Gakuji Kiyonaka, Yoshihiro Furuya, Yusuke Suzuki
  • Method of modulating stress-activated protein kinase system
    Patent number: 9527816
    Abstract: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: December 27, 2016
    Assignee: InterMune, Inc.
    Inventors: Lawrence M. Blatt, Scott D. Seiwert, Leonid D. Beigelman, Ramachandran Radhakrishnan, Karl Kossen, Vladimir Serebryany
  • Anti-fibrotic pyridinones
    Patent number: 9359379
    Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: June 7, 2016
    Assignee: InterMune, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Johnnie Y. Ramphal, Kumaraswamy Emayan, Scott D. Seiwert
  • Compounds and methods for treating inflammatory and fibrotic disorders
    Patent number: 9290450
    Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: March 22, 2016
    Assignee: InterMune, Inc.
    Inventors: Karl Kossen, Scott D. Seiwert, Vladimir Serebryany, Donald Ruhrmund, Leonid D. Beigelman, Luca Francesco Mario Raveglia, Stefania Vallese, Ivana Bianchi, Tao Hu
  • Methods of Improving Microvascular Integrity
    Publication number: 20160022654
    Abstract: The disclosure relates to methods of preserving or improving microvascular integrity in a patient in need thereof comprising administering pirfenidone therapy to the patient.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Applicants: INTERMUNE, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Mark R. Nicolls, Karl Kossen, Alan Cohen
  • PIRFENIDONE AND ANTI-FIBROTIC THERAPY IN SELECTED PATIENTS
    Publication number: 20150164874
    Abstract: The present invention relates to methods of treating pulmonary fibrosis with pirfenidone and/or other agents.
    Type: Application
    Filed: May 25, 2012
    Publication date: June 18, 2015
    Applicant: INTERMUNE, INC.
    Inventor: Williamson Z. Bradford
  • Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
    Patent number: 9017722
    Abstract: A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 28, 2015
    Assignee: Intermune, Inc.
    Inventors: Gakuji Kiyonaka, Yoshihiro Furuya, Yusuke Suzuki
  • Lysophosphatidic acid receptor antagonists
    Patent number: 8975235
    Abstract: Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: March 10, 2015
    Assignee: InterMune, Inc.
    Inventors: Brad O. Buckman, John B. Nicholas, Kumaraswamy Emayan, Scott D. Seiwert
  • PROTEOMIC IPF MARKERS
    Publication number: 20140286929
    Abstract: Provided herein are novel biomarkers for the identification, prediction or monitoring of fibrotic pulmonary diseases (e.g. idiopathic pulmonary fibrosis (IPF)). The biomarkers provided herein may further be used for therapeutic treatment of IPF.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Applicant: Intermune, Inc.
    Inventors: Karl Kossen, Xiaoli Qin, Sharlene R. Lim, Scott S. Seiwert, Donald Ruhrmund
  • Method for Preparing a Granulate Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
    Publication number: 20140242159
    Abstract: A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Applicant: INTERMUNE, INC.
    Inventors: Ramachandran Radhakrishnan, Ronald Vladyka, Kenneth Sultzbaugh
  • COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS
    Publication number: 20140235637
    Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 21, 2014
    Applicant: InterMune, Inc.
    Inventors: Karl Kossen, Scott D. Seiwert, Vladimir Serebryany, Donald Ruhrmund, Leonid D. Beigelman, Luca Francesco Mario Raveglia, Stefania Vallese, Ivana Bianchi, Tao Hu
  • Compounds and methods for treating inflammatory and fibrotic disorders
    Patent number: RE47142
    Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. Mederski et al., Tetrahedron (1999), 55(44), 12757-12770.* Azuma et al., “A placebo control and double blind phase II clinical study of pirfenidone in patients with idiopathic pulmonary fibrosis in Japan”, Am J Respir Crit Care Med., 165:A729 (2002). Badger, et al.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 27, 2018
    Assignee: InterMune, Inc.
    Inventors: Karl Kossen, Scott D. Seiwert, Vladimir Serebryany, Donald Ruhrmund, Leonid Beigelman, Luca Francesco Mario Raveglia, Stefania Vallese, Ivana Bianchi, Tao Hu